Regeneron Pharmaceuticals, a leading biotechnology company announced initial clinical data for REGN5458, a BCMAxCD3 bispecific antibody, in patients with relapsed or refractory (R/R) multiple myeloma.
LBL-034 is an investigational GPRC5D-targeted CD3 bispecific antibody. The Food and Drug Administration (FDA) has granted Orphan Drug designation to LBL-034 for the treatment of multiple myeloma.
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する